Cure My Disease

Don't miss your cure!

 Log in / Sign up

Patients rate their symptoms after starting secukinumab for hidradenitis suppurativa

NCT ID NCT06444087

Ongoing Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 192 adults with hidradenitis suppurativa (a painful skin condition) who are starting secukinumab as part of their normal care. Researchers will ask patients to rate their pain, oozing, and bad smell after 12 months. The goal is to understand how the drug affects symptoms from the patient's point of view, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If successful, this study could show how well secukinumab works from the patient's perspective, helping doctors better understand its real-world benefits for hidradenitis suppurativa.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors other than the drug. It only follows patients for 12 months and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA

Contacts and locations

Locations

  • Novartis Investigative Site

    Nice, France, 06000, France

  • Novartis Investigative Site

    Antony, 92160, France

  • Novartis Investigative Site

    Bordeaux, 33075, France

  • Novartis Investigative Site

    Brest, 29609, France

  • Novartis Investigative Site

    Calais, 62100, France

  • Novartis Investigative Site

    Dijon, 21000, France

  • Novartis Investigative Site

    La Rochelle, 17019, France

  • Novartis Investigative Site

    Le Mans, 72000, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Lorient, 56322, France

  • Novartis Investigative Site

    Lyon, 69003, France

  • Novartis Investigative Site

    Marseille, 13008, France

  • Novartis Investigative Site

    Martigues, 13500, France

  • Novartis Investigative Site

    Montpellier, 34090, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Paris, 75014, France

  • Novartis Investigative Site

    Rodez, 12000, France

  • Novartis Investigative Site

    Rouen, 76031, France

  • Novartis Investigative Site

    Saint-Mandé, 94160, France

  • Novartis Investigative Site

    Saint-Pierre, 97410, France

  • Novartis Investigative Site

    Toulouse, 31400, France

  • Novartis Investigative Site

    Vannes, 56000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.